The Lightning Strike
Silence Therapeutics (SLN) is the “Lightning Strike” in Porter Stansberry’s Ignition Point pitch, the small, speculative name meant to deliver the barbell’s home-run swing. Porter Stansberry, the founder of Porter & Co. and the name behind the long-running Stansberry newsletter family, sizes this kind of pick at a tiny fraction of a portfolio, and the math here shows why. The company trades near $11.51 with a market cap around $764 million, making it the smallest and riskiest name in the group. For the full backstory, see our Porter & Co.’s ‘Ignition Point’ — The Five Gene-Silencing… article.
The pitch centers on a single drug, zerlasiran, and a single eye-catching number: a reduction in Lp(a) of up to 99 percent. That number is real, but it is doing more work in the promo than it can support.
The Mechanism Behind Zerlasiran
Zerlasiran is a small interfering RNA, or siRNA, built to silence the gene that tells the liver to make lipoprotein(a). By turning that gene down, the drug cuts the supply of Lp(a) at the source, which is why it can produce reductions as deep as the 99 percent figure the promo quotes. The mechanism is real, and it is the same biological idea that anchors the whole Ignition Point pitch.
The catch is the one that runs through every name in this cluster: Lp(a) is a biomarker, not a disease. Cutting it by 99 percent in a Phase I trial tells you the drug hit its molecular target, an essential first step. It does not tell you that patients live longer or suffer fewer heart attacks, because Phase I trials are small, short, and measured on safety and dosing, not on outcomes.
That is not a criticism of the science. It is a description of how drug development works. Every medicine that eventually saves lives starts by proving it hits its target, and zerlasiran has cleared that first hurdle convincingly. The remaining hurdles, a Phase 2, a Phase 3, and an outcomes trial, are where most candidates fail, and those still lie ahead.
The 99 Percent Claim
The “up to 99 percent reduction” that anchors the Lightning Strike pitch came out of a Phase I trial, and it refers to a reduction in Lp(a), a blood biomarker. That is a genuine scientific result, and it is a strong one. Slashing Lp(a) that far is exactly what a gene-silencing drug is designed to do, and it is a meaningful step toward treating the condition.
What the number is not is a clinical outcome. A biomarker reduction in a Phase I study of a small group of patients does not prove that heart attacks or strokes actually go down. The distinction is the single most important thing to understand about this pick, and it is the same trap that caught the promo’s own ballast name. We unpack it fully in our endpoint problem explainer.
No Phase 3 Partner
The second thing to weigh is the company’s position. Silence Therapeutics has no Phase 3 partner for zerlasiran, which means the expensive late-stage trial that would actually answer the outcome question is something the company would have to fund and run largely on its own.
That is a heavy lift for a company with a market cap under $1 billion and no meaningful revenue. A late-stage cardiovascular outcomes trial runs years and costs hundreds of millions of dollars, and that is before the question of whether the drug clears the bar that the earlier pelacarsen result just raised. The company’s cash is said to stretch into 2028, which helps, but the path to proving zerlasiran works is long and expensive, and no deep-pocketed partner has signed on to share it yet.
The Context
Silence Therapeutics is not alone in chasing Lp(a). The competition is larger and better funded. Amgen has olpasiran, and Eli Lilly has lepodisiran, and both carry bigger balance sheets and more experienced late-stage teams behind them. The full field is laid out in our Lp(a) drug race explainer.
The good news for Silence Therapeutics is that the prize is large. Cardiovascular disease remains a leading cause of death, and a working Lp(a) drug would address a risk factor that statins cannot touch, which is why the biggest names in the industry are crowding into the same race.
That does not mean zerlasiran cannot win. It means the Lightning Strike is a genuine lottery ticket rather than the near-certainty the promo’s framing implies. The science is credible, the number is real, but a 99 percent biomarker reduction in Phase I is the starting line of a race, not the finish, and the finish line here is years and hundreds of millions of dollars away.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.